人结直肠癌组织CD4<sup>+</sup>、CD8<sup>+</sup> T淋巴细胞与患者预后的关系

doi:10.3969/j.issn.2095-9400.2020.01.006

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1663 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the association of CD4+, CD8+ T lymphocytes in colorectal cancer with postoperative prognosis. Methods: Clinical data and resection samples of 109 colorectal cancer patients identified by pathology undergoing resection in our department from January 2012 to January 2014 were collected. The CD4+, CD8+ T lymphocytes in colorectal cancer were detected by immunohistochemical staining and grouped according to the high and low levels. Kaplan-Meier survival curve analysis was used to compare clinical features and prognosis. The Cox proportional hazard regression model was used to analyze the clinical factors that may affect the prognosis of patients with univariate and multivariate analysis. Results: Immunohistochemical staining showed that CD8+ T cell infiltration was high in 78 cases, low in 31 cases; CD4+ T cell infiltration was high in 56 cases, and low level in 53 cases. The levels of CD4+ and CD8+ T lymphocytes in colorectal cancer tissues were closely related to tumor stage and depth of invasion (all P<0.05). Follow-up analysis showed that colorectal cancer patients with high levels of CD8+ and their CD8+/CD4+ had a better prognosis for DFS and OS (P<0.05). And there was no significant difference between DFS, OS and low-level group in patients with high-level CD4+ colorectal cancer. Cox regression model analysis showed that tumor stage, lymph node metastasis, CD8+ and CD8+/CD4+ were independent risk factors for DFS and OS prognosis in patients with colorectal cancer (P<0.05). Conclusion: The level of CD8+ and CD8+/CD4+ could be a good reference value for the prognosis of colorectal cancer patients.

Key words： colorectal cancer CD4+ CD8+ prognosis

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FU Chao
	MEI Tingting
	WANG Hongtao
	TAO Yong
	WANG Dong
	QIU Jianming
	YANG Guangen

URL:

https://xb.wmu.edu.cn/EN/10.3969/j.issn.2095-9400.2020.01.006 OR https://xb.wmu.edu.cn/EN/Y2020/V50/I1/30

[1] WEINBERG B A, MARSHALL J L, SALEM M E. The growing challenge of young adults with colorectal cancer[J]. Oncology (Williston Park), 2017, 31(5): 381-389.
[2] CREMONESI E, GOVERNA V, GARZON J F G, et al. Gut microbiota modulate T cell trafficking into human colorectal cancer[J]. Gut, 2018, 67(11): 1984-1994.
[3] GARNELO M, TAN A, HER Z, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma[J]. Gut, 2017, 66(2): 342-351.
[4] DUSHYANTHEN S, TEO Z L, CARAMIA F, et al. Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer[J]. Nat Commun, 2017, 8(1): 606.
[5] LOHNEIS P, SINN M, BISCHOFF S, et al. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma[J]. Eur J Cancer, 2017, 83: 290-301.
[6] HORN T, LAUS J, SEITZ A K, et al. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer[J]. World J Urol, 2016, 34(2): 181-187.
[7] KOI M, CARETHERS J M. The colorectal cancer immune microenvironment and approach to immunotherapies[J]. Future Oncol, 2017, 13(18): 1633-1647.
[8] REEVES E, JAMES E. Antigen processing and immune regulation in the response to tumours[J]. Immunology, 2017, 150(1): 16-24.
[9] DAS D, SARKAR B, MUKHOPADHYAY S, et al. An altered ratio of CD4+ and CD8+ T lymphocytes in cervical cancer tissues and peripheral blood-A prognostic clue?[J]. Asian Pac J Cancer Prev, 2018, 19(2): 471-478.
[10] CAVNAR M J, TURCOTTE S, KATZ S C, et al. Tumor-associated macrophage infiltration in colorectal cancer liver metastases is associated with better outcome[J]. Ann Surg Oncol, 2017, 24(7): 1835-1842.
[11] GOVERNA V, TRELLA E, MELE V, et al. The interplay between neutrophils and cd8+ T cells improves survival in human colorectal cancer[J]. Clin Cancer Res, 2017, 23(14): 3847-3858.
[12] TRAN E, ROBBINS P F, LU Y C, et al. T-cell transfer therapy targeting mutant kras in cancer[J]. N Engl J Med, 2016, 375(23): 2255-2262.
[13] DONG C. Helper T cells and cancer-associated inflammation: A new direction for immunotherapy?[J]. J Interferon Cytokine Res, 2017, 37(9): 383-385.
[14] OSTROUMOV D, FEKETE-DRIMUSZ N, SABOROWSKI M, et al. CD4 and CD8 T lymphocyte interplay in controlling tumor growth[J]. Cell Mol Life Sci, 2018, 75(4): 689-713.
[15] Zhu X W, Zhu H Z, Zhu Y Q, et al. Foxp3 expression in CD4+CD25+Foxp3+ regulatory T cells promotes development of colorectal cancer by inhibiting tumor immunity[J].J Huazhong Univ Sci Technolog Med Sci, 2016, 36(5): 677-682
[16] YU W, WANG Y, GUO P. Notch signaling pathway dampens tumor-infiltrating CD8+ T cells activity in patients with colorectal carcinoma[J]. Biomed Pharmacother, 2018, 97: 535-542.
[17] LI K, BAIRD M, YANG J, et al. Conditions for the generation of cytotoxic CD4(+) Th cells that enhance CD8(+) CTL-mediated tumor regression[J].Clin Transl Immunology, 2016, 5(8): e95.
[18] ZHANG Q, HAO C, CHENG G, et al. High CD4+T cell density is associated with poor prognosis in patients with non-muscle-invasive bladder cancer[J]. Int J Clin Exp Pathol, 2015, 8(9): 11510-11516.
[19] MATSUMOTO H, THIKE A A, LI H, et al. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple- negative breast cancer[J]. Breast Cancer Res Treat, 2016, 156(2): 237-247.
[20] YANG C, CHENG H, LUO G, et al. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system[J]. Eur J Surg Oncol, 2017, 43(11): 2112-2118.